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MAST CELL DEPLETING PROPERTIES OF NEOMYCIN*
WOLFGANG P. RAAB, M.D.
Neomycin, With its broad anti-bacterial
spectrum and excellent tolerance by the human
skin, has become one of the most Widely used
bacteriostatic agents in topical dermatologi-
cals and cosmetics. Although allergic contact
type skin reactions due to neomycin have
been reported (1, 2), in view of the extensive
use of this topical antibiotic, the rate of
sensitization to neomycin is quite low.
For the detection of neomycin sensitivity,
intracutaneous tests with 0.1 ml of neomycin
solutions up to 1% have been recommended
(3, 4) in cases Where epicutaneous testing
gives no reaction.
Chemically, neomycin is an antibiotic of
basic character. Such antibiotics, e.g. poly-
myxin B, are known to possess mast cell de-
pleting properties (5). Mast cell depletion,
morphologically characterized as degranula-
tion, provokes liberation of biologically ac-
tive substances ("mediator substances"), e.g.
histamine. Intracutaneous injection of mini-
mal amounts of mast cell depleting sub-
stances, e.g. 10 g Compound 48/80, elicits a
wheal and a flare, lasting for 40 to 180 minutes
(6). Higher amounts of mast cell depleting
substances, e.g. amounts over 50 pg Com-
pound 48/80, provoke dermal papular reac-
tions, lasting for days or months (6). Con-
sidering the importance of dermal reactions
to neomycin in cutaneous tests, it seemed of
interest to investigate neomycin for mast cell
depleting activity.
METHODS AND RESULTS
I. Histologic Observations in the Skin
of Guinea Pigs and Rats
Utilizing an established and successful model
for the detection of mast cell degranulating prop-
erties that has been described previously (7, 8),
the nuchal areas of 10 guinea pigs, 5 mice and 5
rats received intracutaneous injections (0.1 ml)
of neomycin sulfate (Squibb and Sons, Inc.) in
saline in several concentrations from 0.001 to 1%.
Control animals received injections of 0.1 ml
saline. Biopsy specimens of the treated sites were
removed at 0.5, 3 and 24 hour intervals following
injection and stained with toluidine blue (see Table
I for results).
II. Dc granulation of Isolated Mast Cells
The influence of neomycin solution in several
concentrations (0.001—1%) upon a suspension of
isolated peritoneal rat mast cells was studied by the
procedure described by Schwartz, et al (9). The
percentage of degranulated mast cells were deter-
mined after 10 and 20 minute intervals and com-
pared against both a positive control, a 0.1% solu-
tion of Compound 48/80 (5) and a negative
control, saline (see Table II for results).
III. Wheat Test in Rat Skin
Rats under anaesthesia (20 animals were used)
were injected intravenously with a 1% solution
of trypan blue in saline (50 mg trypan blue per
kg body weight). Five minutes later, 0.1 ml of
neomycin solutions (0.001%, 0.01%, 0.1%, 0.5%
and 1%) were injected intracutaneously in shaved
areas of the left side of the abdomen. In cor-
responding sites of the shaved right side of the
abdomen, varying amounts of histamine (100 gig,
20 jig, 10 jig, 5 jig) in 0.1 ml of saline were injected.
Fifteen minutes later, the animals were killed
and the abdominal skin removed. Skin specimens
were mounted on watch glasses with the lower
surface (subeutis) towards the glass. The size of
the stained area and its color intensity arc
directly related to the amount of edema produced.
Saline-injected rat skin does not produce a
stained area. An intracutaneous injection of 0.1
ml of a 1% neomycin solution provoked the same
degree of edema as 20 jig of histamine; 0.1 ml
of a 0.5% neomycin solution corresponded to 10
jig of histamine, while a 0.1% neomycin solution
produced a mild edema only. Neomycin solutions
of 0.01% and 0.001% did not cause edema.
Additional experiments were performed to
determine the time of maximal edema formation.
For this purpose, animals were killed at different
time intervals following injections of neomycin.
It was shown that the highest degree of edema
formation is present 20 minutes after injection
of neomycin. These results, in accordance with
the work of Amann and Radenbach (10), confirm
the histamine liberating effect of neomycin on
isolated rat skin.
IV. Oxygen Consumption of Minced
Guinea Pig Lung
As previously reported (11), the addition of
mast cell depleting substances to minced guinea
pig lung provokes an increase in oxygen consump-
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Neomycin
Biopsy time —.—
1% 0.1% 0.01% 0.001%
Guinea pigs
0.5 hours
3hours
24hours
Rats and
mice
3hours
24hours
18
33
75
40
81
12
20
56
25
53
—
12
21
15
24
—
8
10
12
11
8
5
7
10
8
TABLE II
Degranulation of rat mast cells in vitro
Percentage of degrsnulated
mast cells
10 minutes 20 minutes
Neomycin sulfate
1%
0.1%
0.01%
0.001%
Compound 48/80
0.1%
Saline
60
40
25
12
98
2—8%
95
75
35
20
100
3—18%
tion (Warburg respiration method). Such an effect
has been demonstrated with compound 48/80,
polymyxin B and certain snake poisons. The addi-
Lion of neomycin sulfate (50 pg, 5 pg) to suspen-
sions of minced guinea pig lung produces a signifi-
cant increase in oxygen consumption. This effect
may be attributed to the pharmacologic actions
of bistamine since histamine itself provokes an
increase in oxygen consumption (See Table III
for a compilation of the data). The results sup-
port the opinion that neomycin possesses mast cell
depleting activity and liberates histamine (and
otber biologically active substances) from guinea
pig lung.
DIsCUssION
The experiments described above establish
the mast cell depleting and histamine liberat-
ing action of neomycin in laboratory ani-
mals. It might be assumed from our knowl-
edge of the reliability of test models in
immunology that neomycin is capable of similar
activity in man. It is reasonable to deduce
that intracutaneous tests with neomycin solu-
tions in concentrations of 0.1% or 1% yield
positive reactions (wheal and flare) reflecting
mast cell depletion and liberation of bio-
logically active substances from mast cells in
dermal connective tissue. The different experi-
ments permit an estimation of mast cell de-
pleting power of neomyein, being at least one
tenth of the mast cell depleting power of
Compound 45/80. With this relation, the
intracutaneous injection of 1 mg of neomycin
(=0.1 ml of a 1% solution) equals 100 tg
Compound 45/SO. Intraeutaneous injection of
such amount of Compound 48/SO has been
shown to provoke dermal papular reactions in
man (6). This must lead to a very critical
evaluation of intracutaneous tests with highly
concentrated neomycin solutions. In addition
to possibly harvesting false positive results
from skin testing, such tests may actually
produce true neomycin sensitivity (12).
In patients with atopic dermatitis, mast
cells of dermal connective tissue reveal an
abnormally high tendency to degranulate (5).
It has been shown with iontophoresis that
TABLE III
Oxygen uptake of minced guinea pig lung under the
influence of mast cell depleting substances
and histamine
Addition pl 02/mg tissue/SO Increase
TABLE I
Percentage of degranulaling mast cells in dermal
connective tissue following injections
of neomycin
0.506 0.051
(mean of 20
exp.)
Ringer so-
lution
Neomycin
sulfate
(10 exp.)
500 pg
50 pg
Spg
0.5 pg
Compound
48/80
10 pg
Histamine
20 pg
0.544
0.587
0.622
0.501
0.093
0.071
0.060
0.087
8%
16%
23%
(P < 0.001)
(P < 0.001)
0.581 0.071
(mean of 12
exp.)*
0.617 0.061
(mean of 19
exp.)*
15% (P < 0.001)
22% (P < 0.001)
* See Ref. 9.
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patients with eczema have a decreased thresh-
old to Compoi.md 48/80 (13). These facts to-
gether with the data presented above might
give an explanation for the higher incidence
of neomycin reactions in atopic individuals
(14).
Derruatologic and cosmetic preparations
contain neomycin only in relatively low con-
centrations. The application of such prepara-
tions on intact skin will not cause mast cell
depletion in dermal connective tissue, as nco-
mycin does not readily permeate skin. In
acutely inflamed dermatolcgic lesions, how-
ever, intolerance to neomycin containing prep-
parations might be the result of such mast
cell depleting action of absorbed neomycin.
This assumption is confirmed by preliminary
experiments in human volunteers (16) reveal-
ing urticarial inflammatory responses to in-
tracutaneous injections of highly concen-
trated neomycin (1%) and to application of
neomycin solutions (20%, 40%) to stripped
skin areas.
SUMMARY
Clinical evidence and pharmacological re-
activity gave rise to the suspicion that neo-
mycin might possess mast cell depleting prop-
erties. Experiments were carried out to probe
this question in reliable immunologic test
models. In four procedures, the mast cell de-
pleting action of neomycin in laboratory ani-
mals was clearly demonstrated. The clinical
significance of this finding is briefly dis-
cussed.
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